Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 10

recruiting
3 987
countries
28
conditions
2 109

4 235 trials match your criteria

Acute myeloid leukaemia

Recruiting

Study on RVU120 and Venetoclax for Patients with Acute Myeloid Leukemia After Previous Treatment Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax

Neoplasm malignant

Recruiting

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Arteriosclerosis

Recruiting

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab

Hepatic cirrhosis+2

Recruiting

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin

Amyotrophic lateral sclerosis

Recruiting

Study on the Safety and Effectiveness of Dazucorilant for Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dazucorilant

Ductal adenocarcinoma of pancreas

Recruiting

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Neoplasm malignant

Recruiting

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Type 1 diabetes mellitus

Recruiting

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib

Type 1 diabetes mellitus

Recruiting

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib

Guillain-Barre syndrome

Recruiting

A Study of ANX005 for Patients Recently Diagnosed with Guillain-Barré Syndrome to Evaluate How the Drug Works in the Body and Its Safety

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Humanised IgG4 monoclonal antibody against C1Q

Non-small cell lung cancer

Recruiting

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.